Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bristol Myers Squibb (BMYMP) EBIT (2016 - 2025)

Bristol Myers Squibb (BMYMP) has disclosed EBIT for 17 consecutive years, with -$2.6 billion as the latest value for Q4 2025.

  • Quarterly EBIT rose 43.35% to -$2.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$4.6 billion through Dec 2025, up 79.38% year-over-year, with the annual reading at -$4.6 billion for FY2025, 79.38% up from the prior year.
  • EBIT for Q4 2025 was -$2.6 billion at Bristol Myers Squibb, down from -$321.0 million in the prior quarter.
  • The five-year high for EBIT was $204.0 million in Q1 2023, with the low at -$14.4 billion in Q1 2024.
  • Average EBIT over 5 years is -$1.7 billion, with a median of -$773.0 million recorded in 2022.
  • The sharpest move saw EBIT soared 126.02% in 2023, then plummeted 7182.35% in 2024.
  • Over 5 years, EBIT stood at -$498.0 million in 2021, then tumbled by 47.39% to -$734.0 million in 2022, then plummeted by 45.91% to -$1.1 billion in 2023, then tumbled by 332.96% to -$4.6 billion in 2024, then skyrocketed by 43.35% to -$2.6 billion in 2025.
  • According to Business Quant data, EBIT over the past three periods came in at -$2.6 billion, -$321.0 million, and -$1.6 billion for Q4 2025, Q3 2025, and Q2 2025 respectively.